APOE ϵ4 Association with Cognition and Alzheimer Disease Biomarkers in down Syndrome - Implications for Clinical Trials and Treatments for All

TY - JOUR

T1 - APOE ϵ4 Association with Cognition and Alzheimer Disease Biomarkers in down Syndrome - Implications for Clinical Trials and Treatments for All

AU - Lemere, Cynthia A.

AU - Head, Elizabeth

AU - Holtzman, David M.

N1 - Funding Information: reported receiving personal fees for consulting from Acumen, Apellis, Biogen, and Cambridge Healthcare Research; serving on the scientific advisory board of Cognition Therapeutics; and receiving nonfinancial support from Vivoryon Therapeutics NV outside the submitted work. Dr Head reported receiving grants from the National Institutes of Health (NIH) and the BrightFocus Foundation and personal fees for consulting from AC Immune. Dr Holtzman reported serving on the scientific advisory board of C2N Diagnostics, Denali, and Cajal Neurosciences; receiving personal fees for consulting from Genentech, Merck, and Eli Lilly outside the submitted work; holding a patent on anti-tau antibodies licensed to AbbVie and a patent on anti-apoE antibodies; and receiving a grant for anti-apoE antibodies research from NextCure.

PY - 2021/8

Y1 - 2021/8

UR - https://www.scopus.com/pages/publications/85113116815

U2 - 10.1001/jamaneurol.2021.1649

DO - 10.1001/jamaneurol.2021.1649

M3 - Review article

C2 - 34228117

AN - SCOPUS:85113116815

SN - 2168-6149

VL - 78

SP - 913

EP - 915

JO - JAMA Neurology

JF - JAMA Neurology

IS - 8

ER -